FOR IMMEDIATE RELEASE

Sun Pharma to announce third quarter results on February 12, 2016


Earnings call (06.30 pm IST, February 12, 2016)

The Company will conduct an hour long call at 06.30 pm IST on February 12, 2016 where senior management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

<table>
<thead>
<tr>
<th>Event</th>
<th>Date and time</th>
<th>Telephone number/ website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings release</td>
<td>February 12, 2016</td>
<td><a href="http://www.sunpharma.com">www.sunpharma.com</a></td>
</tr>
</tbody>
</table>
| Earnings conference call | 06.30 pm IST, February 12, 2016 | Primary Number : +91 22 3960 0899  
Secondary Number : +91 22 6746 8324  
Via audio webcast, details of which will be made available on www.sunpharma.com |
| Replay of conference call | February 12, 2016 to February 19, 2016 | India: +91 22 3065 2322  
+91 22 6181 3322  
ID: 61080  
Via audio webcast playback, details of which will be made available on www.sunpharma.com |
About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma’s global presence is supported by 49 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The consolidated revenues for 12 months ending March 2015 are approximately US$ 4.5 billion, of which US contributes US$ 2.2 billion. In India, the company enjoys leadership across 12 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues. For further information please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

Contacts

Nimish Desai
Tel +91 22 4324 4324, Xtn 2778
Tel Direct +91 22 4324 2778
Mobile +91-98203 30182
E mail nimish.desai@sunpharma.com

Frederick Castro
Tel +91 22 4324 4324, Xtn 2777
Tel Direct +91 22 4324 2777
Mobile +91 99206 65176
E mail frederick.castro@sunpharma.com